AD

ADC Therapeutics SANYSE ADCT Stock Report

Last reporting period 30 Jun, 2024

Updated 05 Nov, 2024

Last price

Market cap $B

0.295

Micro

Exchange

XNYS - New York Stock Exchange, Inc

ADCT Stock Analysis

AD

Uncovered

ADC Therapeutics SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-33/100

Low score

Market cap $B

0.295

Dividend yield

Shares outstanding

80.642 B

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 317 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

View Section: Eyestock Rating